Chiron Corporation
Records under this name other than patents Chiron Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,217,035 | Pyrimidine Derivatives Used as PI-3-Kinase Inhibitors now held by Novartis AG In force · High confidence | In force | High confidence | |
| US 7,754,686 | Stabilized FGF Formulations Containing Reducing Agents now held by Novartis Vaccines and Diagnostics, Inc. In force · High confidence | In force | High confidence | |
| US 9,393,215 | Nanoparticles For Use In Immunogenic Compositions now held by GlaxoSmithKline Biologicals S.A. In force · High confidence | In force | High confidence | |
| US 7,563,873 | Rabbit Monoclonal Antibodies to Hepatitis B Surface Antigens and Methods of Using the Same now held by Grifols Worldwide Operations Limited Term ended Term ended May 5, 2026 · High confidence | Term ended | Term ended May 5, 2026 | High confidence |
| US 7,871,625 | HCV Multiple Epitope Fusion Antigens with Modified Proteolytic Cleavage Sites and Uses Thereof now held by Grifols Worldwide Operations Limited Term ended Term ended Feb 24, 2026 · High confidence | Term ended | Term ended Feb 24, 2026 | High confidence |
| US 8,772,255 | Cell Transfecting Formulations of Small Interfering RNA Related Compositions and Methods of Making and Use merged into Novartis Vaccines and Diagnostics, Inc. Term ended Term ended Nov 4, 2025 · Medium confidence | Term ended | Term ended Nov 4, 2025 | Medium confidence |
| US 8,563,549 | Pyrimidine Derivatives Used as PI-3 Kinase Inhibitors now held by Novartis AG Lapsed on the fee record Ended Oct 22, 2025 · High confidence | Lapsed on the fee record | Ended Oct 22, 2025 | High confidence |
| US 9,107,831 | Immunogenic compositions containing microparticles comprising adsorbed toxoid and polysaccharide-containing antigens now held by GlaxoSmithKline Biologicals S.A. Term ended Term ended Jun 2, 2024 · High confidence | Term ended | Term ended Jun 2, 2024 | High confidence |
| US 7,731,967 | Compositions for Inducing Immune Responses now held by GlaxoSmithKline Biologicals S.A. Term ended Term ended Apr 29, 2024 · High confidence | Term ended | Term ended Apr 29, 2024 | High confidence |
| US 8,529,906 | Compositions for Inducing Immune Responses now held by GlaxoSmithKline Biologicals S.A. Term ended Ended no later than Apr 29, 2024 · Medium confidence | Term ended | Ended no later than Apr 29, 2024 | Medium confidence |